BofA raised the firm’s price target on Elevance Health to $646 from $621 and keeps a Buy rating on the shares. The firm says that “using somewhat conservative assumptions,” it estimates that Elevance should return 20% over the next year, adding that it sees “a path to consistent additional low teens annual returns from there” and is raising its multiple on better visibility into growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Early notable gainers among liquid option names on May 31st
- Elevance Health price target raised to $631 from $628 at JPMorgan
- Elevance Health initiated with an Outperform at Baird
- UnitedHealth slides after warning on âdisturbanceâ ahead in Medicaid business
- Elevance Health price target raised to $585 from $575 at Mizuho